Physician profile
Mark A Weiner
NPI 1114901253
$1,284.47
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $22.65 · 2021: $142 · 2022: $431 · 2023: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $609.34 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $151.26 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $147.02 | 2022-2023 | Rexulti |
| Abbvie INC. | $134.51 | 2021-2023 | Vraylar |
| Sunovion Pharmaceuticals INC. | $56.33 | 2019 | |
| Pfizer INC. | $36.41 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $29.03 | 2019 | |
| Lilly USA, LLC | $27.49 | 2022 | |
| Glaxosmithkline, LLC. | $27.47 | 2019 | |
| Allergan, INC. | $23.64 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.20 | 2023 | |
| Novartis Pharmaceuticals Corporation | $11.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.